Company: STAA
Filing Date: 2025-12-11
Form Type: DFAN14A
Source: 0001213900-25-120777
Chunk: 5

Company: STAAR SURGICAL CO
Filing Date: 2025-12-11
Form: DFAN14A
Chunk 5
---
.S. to accelerate as surgeons gain confidence with the EVO ICL procedure and patients have positive experiences 3 ▪ STAAR’s growth in the U.S. continues to outpace the U.S. refractive market more broadly “by a large margin” 3 ▪ EMEA sales exceeded management’s initial outlook and STAAR expects to continue to benefit from investments in this important market 1,3 ▪ STAAR’s European distributor markets, as well as Spain and the Middle East, have remained resilient and delivered growth, even in the face of a dynamic geopolitical backdrop and elevated inflation levels 3 1. Source: STAAR Quarterly Reports on Form 10 - Q for the applicable periods. 2. Source: William Blair Growth Stock Conference, June 4, 2025. 3. Source: STAAR Q4 2024 Earnings Call, February 11, 2025. $23 $24 $24 $25 $26 $26 $28 $40 $41 $41 $44 $45 $46 $47 $63 $65 $66 $69 $71 $73 $75 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 Americas EMEA 12% 12% 11% 21% 8% 10% 20% 11% 5% 4% 22% 16% 11% 8% 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 Americas EMEA

Broadwood Partners, L.P. 11% 29% (10%) 14% 2010-2019 2019-2023 2023-2025P 2025P-2030P Historical Growth Rate Pandemic-Related Improvement Short-Term Tactical Challenges Return to Consistent Growth 6% 19% 9% 27% 2010-2019 2019-2023 2023-2025P 2025P-2030P Historical Margin¹ Pandemic-Related Improvement¹ Short-Term Tactical Challenges Accelerating Profitability Net Sales CAGR Average Adjusted EBITDA Margin Management Is Forecasting a Quick Return to Growth and Profitability 8 Source: Historical data from FactSet and STAAR Annual Reports on Form 10 - K for the applicable fiscal years. Projections from STA AR proxy statement on Form DEF